Gelteq Announces Preclinical Findings Demonstrating Effectiveness of Gel Platform

Gelteq announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical development and demonstrate that Gelteq's technology can enhance the oral delivery of oil-soluble and poorly soluble drugs. Across two complementary preclinical studies, the results showed a more rapid absorption of an oil soluble compound in Gelteq's gel base compared to an existing FDA approved reference product, with a 300 percent increase in bioavailability across the first hour. High bioavailability in the first hour is critical for rapid onset of action.Further results demonstrated that the oil soluble compound wasn't just more rapidly absorbed in Gelteq's gel base, but the overall absorption was also improved. Over 24 hours, the absorption was improved by more than 20 percent overall compared to an existing FDA approved reference product. These findings further illustrate that Gelteq's gel matrix can support the delivery of lipophilic compounds whilst moderating the need for high levels of emulsifiers. The study results also demonstrate that Gelteq's platform enables controlled movement through the digestive system, targeted release, and effective absorption while maintaining full clearance of both the active pharmaceutical ingredients and the gel material itself. The GI transit evaluation demonstrated that the gel disperses the active ingredient uniformly along the small intestine. This extended distribution behaviour supports improved absorption through both mucoadhesive interactions and the presentation of the drug across a larger intestinal surface area. The studies also showed that the gel can be formulated to allow efficient transit and rapid early absorption of the API. The gel's structural matrix dispersed and cleared effectively to the large intestine, reinforcing the platform's safety and compatibility with oral administration.